Daftar Obat-Obatan di Indonesia
| # | Nama Produk | Harga | # |
|---|---|---|---|
| 461 | RESPITIDE 25/125 AEROSOL | 169.775,00 | Salmeterol xinafoate 25 mcg, fluticasone propionate 125 mcg. |
| 462 | RESPITIDE AEROSOL 25/250 | 242.535,00 | Tiap metered dose mengandung : Salmeterol xinafoate 25 mcg, Fluticasone propionate 250 mcg |
| 463 | RESPIVENT SOL. FOR INHALATION | 159.563,00 | Ipratropium Br 0.5 mg, salbutamol sulphate 3 mg. |
| 464 | RESPOLIN AUTOHALER | 0,00 | Salbutamol Sulfat. |
| 465 | RESPOLIN INHALER 100 DOSE | 0,00 | Salbutamol Sulfat. |
| 466 | RESPOLIN INHALER 400 DOSE | 0,00 | Salbutamol Sulfat. |
| 467 | RESSAL ACNE LOTION 100 ML | 46.465,00 | Cucumis sativus, Hamamelis Virginiana, Panthenol, Salicylic acid |
| 468 | RESSAL ACNE LOTION 60 ML | 26.807,00 | |
| 469 | RESTADIN TABLET 20 MG | 0,00 | Famotidine. |
| 470 | RESTADIN TABLET 40 MG | 0,00 | Famotidine. |
| 471 | RESTOR TABLET | 61.272,00 | Aspirin / Acetylsalicylic acid (Asam asetilsalisilat) / Asetosal. |
| 472 | RESTYLANE LYFT with LIDOCAINE 1 ML | 2.930.400,00 |
|
| 473 | RESTYLANE SKIN BOOSTER VITAL LIGHT with LIDOCAINE 1 ML | 2.075.700,00 |
|
| 474 | RESTYLANE SKIN BOOSTERS VITAL with LIDOCAINE 1 ML | 2.136.750,00 |
|
| 475 | RESURGIN TABLET | 91.575,00 | Per 3 tablet : glycyrrhizin / Glisirizin 100 mg, Vitamin B2 12 mg, Vitamin B6 6 mg, Kalsium Pantotenat 40 mg, Klorfeniramini Maleat 4 mg, Kalsium Fosfat dibase 300 mg, Nagase 0,4 mg, Biodiasmin F-20 15 mg, Serbuk Kalembak, Scufellariae, dan Coptis 100 mg. |
| 476 | RESVICA CAPLET | 91.575,00 | Bubuk ekstrak daun Grapevine EFLA 266, Ekstrak daun Vitis vinifera 360 mg, Bubuk ekstrak bawang putih EFLA 851 (ekstrak Alivi Sativi bulbus) 165 mg. |
| 477 | RETAB TABLET | 67.155,00 | Attapulgite teraktifasi 650 mg, Pektin / Pectin 50 mg. |
| 478 | RETAB TABLET* | 0,00 | Attapulgite teraktifasi 650 mg, Pektin / Pectin 50 mg. |
| 479 | RETAPHYL SR KAPLET 300 MG | 248.751,00 | Theophyllin / Teofilin etilendiamin. |
| 480 | RETARPEN | 0,00 | Benzathine benzylpenicillin/Benzatin Benzilpenisilin. |